Video of ISMRM: Shintaro ichikawa via MRI biomarker for liver diseases

At the ISMRM conference, Tanteminie Spoken with Shintaro Ichikawa, PhD, from the Hamamatsu University School of Medicine in Yamanashi, Japan. On May 13th, Ichikawa will have the National Institute of Biomedical Imaging and Bioengineering (NIBIBIB) New Horizons Lecture entitled “Quantitative MRI -Biomarker for chronic liver diseases”.

In his chat with TanteminieIchikawa described the advantages of MRI elastography, a technique for evaluating tissue stiffness – which can serve as biomarkers for conditions such as liver fibrosis and cirrhosis.

Ichikawa also examines interdosis interval fraction (IDIF), an MRI biomarker that can evaluate the liver fat content – especially with regard to non -alcoholic fatty liver disease (NAFLD) and non -alcoholic steatohepatitis (Nash).

Finally, Ichikawa informed what he pulled for liver research: “The liver is the largest internal organ and we cannot live without it,” he said.

Checkout Tanteminie Complete coverage of ISMRM 2025 Here.